246 related articles for article (PubMed ID: 32804017)
61. New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia.
van der Velden VH; de Launaij D; de Vries JF; de Haas V; Sonneveld E; Voerman JS; de Bie M; Revesz T; Avigad S; Yeoh AE; Swagemakers SM; Eckert C; Pieters R; van Dongen JJ
Br J Haematol; 2016 Mar; 172(5):769-81. PubMed ID: 26898195
[TBL] [Abstract][Full Text] [Related]
62. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
Schultz KR; Pullen DJ; Sather HN; Shuster JJ; Devidas M; Borowitz MJ; Carroll AJ; Heerema NA; Rubnitz JE; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Gaynon PS; Camitta BM
Blood; 2007 Feb; 109(3):926-35. PubMed ID: 17003380
[TBL] [Abstract][Full Text] [Related]
63. Subgrouping by gene expression profiles to improve relapse risk prediction in paediatric B-precursor acute lymphoblastic leukaemia.
Huang Q; Zhong J; Gao H; Li K; Liang H
Cancer Med; 2021 Jun; 10(11):3782-3793. PubMed ID: 33987975
[TBL] [Abstract][Full Text] [Related]
64. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
65. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
66. MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB.
Cordas Dos Santos DM; Eilers J; Sosa Vizcaino A; Orlova E; Zimmermann M; Stanulla M; Schrappe M; Börner K; Grimm D; Muckenthaler MU; Kulozik AE; Kunz JB
BMC Cancer; 2018 Jun; 18(1):663. PubMed ID: 29914415
[TBL] [Abstract][Full Text] [Related]
67. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
[TBL] [Abstract][Full Text] [Related]
68. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
69. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.
Krentz S; Hof J; Mendioroz A; Vaggopoulou R; Dörge P; Lottaz C; Engelmann JC; Groeneveld TW; Körner G; Seeger K; Hagemeier C; Henze G; Eckert C; von Stackelberg A; Kirschner-Schwabe R
Leukemia; 2013 Feb; 27(2):295-304. PubMed ID: 22699455
[TBL] [Abstract][Full Text] [Related]
70. Bone marrow Th2 cytokine expression as predictor for relapse in childhood acute lymphoblastic leukemia (ALL).
Stachel D; Albert M; Meilbeck R; Kreutzer B; Haas RJ; Schmid I
Eur J Med Res; 2006 Mar; 11(3):102-13. PubMed ID: 16751110
[TBL] [Abstract][Full Text] [Related]
71. Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia.
James AR; Schroeder MP; Neumann M; Bastian L; Eckert C; Gökbuget N; Tanchez JO; Schlee C; Isaakidis K; Schwartz S; Burmeister T; von Stackelberg A; Rieger MA; Göllner S; Horstman M; Schrappe M; Kirschner-Schwabe R; Brüggemann M; Müller-Tidow C; Serve H; Akalin A; Baldus CD
J Hematol Oncol; 2019 Jan; 12(1):8. PubMed ID: 30642353
[TBL] [Abstract][Full Text] [Related]
72. Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial.
Attarbaschi A; Panzer-Grümayer R; Mann G; Möricke A; König M; Mecklenbräuker A; Teigler-Schlegel A; Bradtke J; Harbott J; Göhring G; Stanulla M; Schrappe M; Zimmermann M; Haas OA;
Klin Padiatr; 2014 Nov; 226(6-7):338-43. PubMed ID: 25431866
[TBL] [Abstract][Full Text] [Related]
73. Simultaneous changes in expression levels of BAALC and miR-326: a novel prognostic biomarker for childhood ALL.
Ghodousi ES; Aberuyi N; Rahgozar S
Jpn J Clin Oncol; 2020 Jun; 50(6):671-678. PubMed ID: 32129446
[TBL] [Abstract][Full Text] [Related]
74. CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia.
Rhein P; Mitlohner R; Basso G; Gaipa G; Dworzak MN; Kirschner-Schwabe R; Hagemeier C; Stanulla M; Schrappe M; Ludwig WD; Karawajew L; Ratei R
Blood; 2010 May; 115(18):3763-71. PubMed ID: 20228269
[TBL] [Abstract][Full Text] [Related]
75. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia.
Palmi C; Vendramini E; Silvestri D; Longinotti G; Frison D; Cario G; Shochat C; Stanulla M; Rossi V; Di Meglio AM; Villa T; Giarin E; Fazio G; Leszl A; Schrappe M; Basso G; Biondi A; Izraeli S; Conter V; Valsecchi MG; Cazzaniga G; Te Kronnie G
Leukemia; 2012 Oct; 26(10):2245-53. PubMed ID: 22484421
[TBL] [Abstract][Full Text] [Related]
76. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia.
Sędek Ł; Theunissen P; Sobral da Costa E; van der Sluijs-Gelling A; Mejstrikova E; Gaipa G; Sonsala A; Twardoch M; Oliveira E; Novakova M; Buracchi C; van Dongen JJM; Orfao A; van der Velden VHJ; Szczepański T;
J Immunol Methods; 2019 Dec; 475():112429. PubMed ID: 29530508
[TBL] [Abstract][Full Text] [Related]
77. PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy.
Zhang YH; Lu AD; Yang L; Li LD; Chen WM; Long LY; Zhang LP; Qin YZ
Leuk Res; 2017 Jan; 52():43-49. PubMed ID: 27875783
[TBL] [Abstract][Full Text] [Related]
78. DNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemia.
Borssén M; Nordlund J; Haider Z; Landfors M; Larsson P; Kanerva J; Schmiegelow K; Flaegstad T; Jónsson ÓG; Frost BM; Palle J; Forestier E; Heyman M; Hultdin M; Lönnerholm G; Degerman S
Clin Epigenetics; 2018; 10():31. PubMed ID: 29515676
[TBL] [Abstract][Full Text] [Related]
79. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
80. [The Factors Affecting Relapse in Pediatric B-cell Acute Lymphoblastic Leukemia Patients without Prognostic Fusion Genes Following Up for 10 years].
Jiang MY; Gao W; Gao J; Ling J; Pan J; Xiao PF; Lu J; He HL; Wang Y; Li J; Li JQ; Chai YH; Sun YN; Hu SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):12-17. PubMed ID: 35123597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
